Apeiron Therapeutics Presents First-in-Human Data from Phase 1 Clinical Trial of GTA182 in MTAP-Deleted Advanced Non-Small Cell Lung Cancer at the ESMO Asia Congress 2025
GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging early antitumor activity In MTAP-deleted NSCLC, preliminary results show a 57.1% objective response rate and evidence of intracranial activity SAN FRANCISCO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Apeiron Therapeutics, a precision oncology company leveraging structural biology and AI-guided molecular modeling for drug discovery, […]